文献速递浆细胞疾病

埃纳妥单抗治疗复发和/或难治性免疫球蛋白轻链淀粉样变患者的安全性与疗效

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.
PubMed 文献 · Blood · 2025-01-01

该研究报告了9例连续接受埃纳妥单抗单药治疗的晚期AL淀粉样变患者,总缓解率100%、完全缓解率67%(包括微小残留病阴性),中位血液学缓解时间9天(范围6-24天),并在3至6个月观察到心脏和肾脏缓解。作者认为这些数据支持开展前瞻性研究探索埃纳妥单抗用于复发AL淀粉样变。

要点

  • 9例晚期AL淀粉样变患者接受埃纳妥单抗单药治疗,总缓解率100%,完全缓解率67%。
  • 中位血液学缓解时间9天(范围6-24天),1个周期内即见受累游离轻链深度抑制。
  • 3至6个月观察到心脏和肾脏缓解,毒性符合预期。

核心结论

  • 埃纳妥单抗在复发和/或难治性AL淀粉样变患者中显示100%总缓解率和67%完全缓解率(包括微小残留病阴性),毒性符合预期。
  • 作者认为这些数据支持开展前瞻性研究探索埃纳妥单抗用于复发AL淀粉样变患者。

研究设计与样本

  • 研究报告了9例连续接受单药埃纳妥单抗治疗的晚期AL淀粉样变患者的安全性和疗效。

主要发现

  • 9例患者总缓解率为100%,完全缓解率为67%,包括微小残留病阴性。
  • 中位血液学缓解时间为9天(范围6-24天),1个周期治疗内即观察到受累游离轻链深度抑制。
  • 治疗3至6个月观察到心脏和肾脏缓解,毒性符合预期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin light-chain (AL) amyloidosis is a plasma cell disorder characterized by progressive organ dysfunction secondary to deposition of organized immunoglobulin light-chain aggregates. Achievement of rapid and deep normalization of involved immunoglobulin free light chains is necessary to maximize chances of reversibility of organ dysfunction, which, in turn, results in improved quality and length of life. There are no US Food and Drug Administration (FDA)-approved therapies for patients with relapsed AL amyloidosis. B-cell maturation antigen-targeting (BCMA)-bispecific T-cell engagers teclistamab and elranatamab have shown high activity and acceptable safety profile in patients with relapsed and/or refractory multiple myeloma, leading to their FDA approval. Herein, we report on safety and efficacy of elranatamab for patients with relapsed and/or refractory AL amyloidosis. We treated 9 consecutive patients with advanced-stage AL amyloidosis with single-agent elranatamab, observing a 100% overall response and 67% complete response rate, including minimal residual disease negativity, with expected toxicities. Median time to hematological response was 9 days (range, 6-24), with deep suppression in involved free light chains observed within 1 cycle of therapy, translating in cardiac and renal responses at 3 to 6 months. These data support prospective studies exploring elranatamab for patients with relapsed AL amyloidosis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Vianna P, Chakraborty R, Hossain S, et al. Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis. Blood. 2025. PMID: 40712156. doi:10.1182/blood.2025028383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。